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Introduction: Neuromyelitis optica is an inflammatory demyelinating disease of the central nervous system. To
date, optimal therapeutic approaches for neuromyelitis optica have yet to be defined. Natalizumab is highly
effective in relapsing-remitting multiple sclerosis and might be considered as an option.
Case presentation: Here, we describe a 67-year-old Caucasian man with definite neuromyelitis optica with detection
of anti-aquaporin-4 antibodies over the course of the disease. After initially discussing the diagnosis of multiple sclerosis
at an outside hospital, our patient received interferon beta 1a as well as repeated corticosteroid pulses without success.
Under subsequent therapy with natalizumab, he continued to present relapses. It was not until discontinuation of
natalizumab, repeated cycles of plasma exchanges and initiation of therapy with rituxan that the disease course started
to stabilize. Although B cells were completely depleted, our patient experienced another severe myelitis relapse during
further follow-up and an additional immunosuppressive therapy with cyclophosphamide was started. Under this
regimen, no further relapses occurred over the next 24 months.
Conclusions: This case adds further evidence to the previously discussed notion that natalizumab, while highly
effective in multiple sclerosis, may not work sufficiently in neuromyelitis optica. It further advocates for repetitive testing
of anti-aquaporin-4 antibodies before and after treatment initiation.
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Neuromyelitis optica (NMO) is an immune-mediated de-
myelinating disease with predominant involvement of the
optical nerve and the spinal cord. In contrast to multiple
sclerosis (MS), NMO is associated with autoantibodies
that target the aquaporin-4 water channel on astrocytes
(anti-AQP-4 antibody). Anti-AQP-4 antibodies have both
high specificity and sensitivity for NMO. AQP-4 seroposi-
tivity has been incorporated as additional criterion for the
diagnosis of NMO [1,2]. For the treatment of NMO, small
trials hint at positive effects of azathioprine, mitoxantrone,
mycophenolate motefil and intravenous immunoglobulins,
while several observations support the opinion that beta in-
terferons have no effects or may even be harmful in NMO
patients [3,4]. Nowadays, monoclonal antibodies targeting
B cells such as rituxan play an increasingly important role* Correspondence: De-Hyung.Lee@uk-erlangen.de
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unless otherwise stated.in NMO therapy [5]. In addition, effects of further mono-
clonals like tocilizumab, eculizumab or natalizumab may be
discussed [6,7].
Case presentation
Without significant previous medical history, a 67-year-old
Caucasian man developed spinal symptoms with temporary
hypesthesia and hypoalgesia in both legs. These symptoms
spontaneously resolved without any specific diagnosis at
that time. At the age of 73, our patient suffered from bilat-
eral optic neuritis and he was diagnosed with MS at an out-
side hospital. His expanded disability status scale (EDSS)
score was at that time 2.5. Magnetic resonance imaging
(MRI) studies of the spinal cord revealed a diffuse cord
swelling and longitudinally extensive T2 hypertensive le-
sions extending from C2 to T3 (see Figure 1 depicting a
T2-weighted MRI scan, which shows residual longitudinal
myelitis with extensive cord atrophy). A cranial MRI scan
displayed few periventricular and cerebellar lesions without
contrast enhancement and without fulfilling the Barkhof. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Spinal cord magnetic resonance imaging (T2-weighted
imaging from C4 to Th6) one year after the start of combination
treatment with rituxan and cyclophosphamide depicting
longitudinally extensive spinal cord lesions (see arrows) with
significant cord atrophy.
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presented oligoclonal bands. At that time, anti-AQP-4 anti-
body testing was not performed. A therapy with interferon
beta 1a was started for six months and was replaced by
interferon beta 1b at the discretion of the treating outside
neurologist. Our patient developed two further spinal re-
lapses during the treatment with interferon beta prepara-
tions. They were treated with corticosteroid pulses without
any success and his EDSS score worsened from 2.5 to 4.0.
Although a subsequent therapy with natalizumab was initi-
ated at an outside clinic, our patient continued to present
another three relapses. The first relapse occurred four
months after starting natalizumab, the second after six
months and the third relapse after eight months. All re-
lapses repeatedly affected both optic nerves and the spinal
cord each with increasing visual and motor impairment.Thus, our patient developed a high-grade spastic tetrapar-
esis as well as impaired visual acuity of both eyes and his
EDSS score progressed from 4.0 to 8.0. At that point,
NMO was discussed after referral to our hospital and nata-
lizumab therapy was discontinued after nine courses. After
repeated cycles of plasma exchange, the disease course sta-
bilized and a therapy with rituxan was started. Although B
cells were completely depleted, our patient experienced an-
other severe myelitis relapse upon further follow-up three
months later. Consequently, an additional immunosuppres-
sive therapy with cyclophosphamide at a dosage of 600mg/
m2 was initiated. In the meantime, we performed repetitive
anti-AQP-4 antibody tests in an approved external labora-
tory employing an immunofluorescence assay (IFA) cell-
based analysis. Negative anti-AQP-4 antibody tests were
obtained via IFA analyses upon first admission and then in
six-monthly intervals after first contact at our hospital. It
was only after 18 months that anti-AQP-4 antibodies
became positive after three negative results. At that time,
the anti-AQP-4-immunoglobulin (Ig)G antibody titer was
1:1000 while IgM and IgA titers were negative. There were
no other autoantibodies and no signs of other autoimmune
diseases or malignancy.
Under combination treatment with cyclophosphamide
(13 cycles every six weeks, cumulative dosage of 8300mg/m2)
followed by another cycle of rituxan, our patient developed
no further relapses over an observation period of 2.5 years.
Conclusions
In this case NMO was initially misdiagnosed as MS,
whereas CSF analysis revealed positive oligoclonal bands
and an MRI scan of the brain presented some periventricu-
lar lesions without fulfilling the Barkhof criteria. However,
oligoclonal bands may be positive in up to 30 percent of
NMO patients and 60 percent of the patients may present
supratentorial lesions [8]. In our patient, no follow-up CSF
analysis was available to check for the persistence of oligo-
clonal bands.
After first- and second-line immunomodulatory therapy
failed, natalizumab was chosen as an escalation therapy at
an outside hospital. In at least one case series and two fur-
ther case reports, a total of six NMO patients presented
continuous relapses or even a deteriorating disease course
under natalizumab, [6,9-11]. Subsequently, these observa-
tions were controversially discussed in the neuroimmuno-
logical community [12]. Our case adds further evidence to
the notion that natalizumab, while highly effective in MS,
may not work sufficiently in NMO. Indeed, natalizumab
does not positively affect the trafficking properties of neu-
trophils, which are abundant in NMO lesions. After natali-
zumab therapy, an increase of B-cell precursors in the
blood is observed, which might be counterproductive in
case of a presumed B-cell-based pathomechanism as in
NMO [13,14].
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combined with cyclophosphamide. While cyclophospha-
mide alone may not work sufficiently in NMO [15], a
combination treatment regime of complete B-cell deple-
tion followed by cyclophosphamide pulses similar to rheu-
matologic disease may be more effective, at least in the
present case. Nowadays, treatment with tocilizumab may
be another option in rituxan-refractory NMO [7].
In our case, a first positive test for anti-AQP-4 anti-
bodies occurred eight years after the onset of his first
symptoms during a severe relapse. It is interesting to dis-
cuss whether this finding represents true seroconversion,
is linked to variable test sensitivities or is governed by test-
ing during a relapse. Indeed, titers of anti-AQP-4 anti-
bodies might reflect the disease activity of NMO patients
[16]. Thus, repeated testing in the active phases of the dis-
ease may prove useful. We thus propose critical testing for
NMO in all patients with poorly controlled autoimmune
central nervous system (CNS) inflammation, especially be-
fore, but also after initiation of natalizumab therapy. If
NMO is clinically suspected but initial anti-AQP-4 anti-
body testing remains negative, repeated tests may be help-
ful to confirm the final diagnosis.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for
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